Fortress Biotech to Participate in Four March 2021 Virtual Investor Conferences

Rhea-AI Summary

Fortress Biotech, Inc. (NASDAQ: FBIO) has announced that its CEO, Lindsay A. Rosenwald, M.D., will participate in four virtual investor conferences throughout March 2021. Key presentations include:

• H.C. Wainwright Global Life Sciences Virtual Conference on March 9.
• Barclays Global Healthcare Virtual Conference on March 11.
• ROTH Conference on March 16.
• Oppenheimer Virtual Healthcare Conference on March 18.

Fortress focuses on developing and commercializing biopharmaceutical products across multiple market areas, enhancing shareholder value.

NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in four virtual investor conferences in March 2021.

Details of the events are as follows:

• H.C. Wainwright Global Life Sciences Virtual Conference: The company’s presentation will be available for on-demand viewing on Fortress’ website beginning on Tuesday, March 9, 2021, at 7:00 a.m. ET and will remain available on the Events page under the News & Media section of Fortress’ website: www.fortressbiotech.com for approximately 30 days following the presentation.
• Barclays Global Healthcare Virtual Conference: The company will present on Thursday, March 11, 2021, at 3:00 p.m. ET and will participate in one-on-one meetings during the conference.
• Virtual 33^rd Annual ROTH Conference: The company will participate in a fireside chat on Tuesday, March 16, 2021, at 11:00 AM ET and will attend one-on-one meetings during the conference. A webcast of the fireside chat will be available on the Events page under the News & Media section of Fortress’ website: www.fortressbiotech.com for approximately 30 days following the chat.
• Oppenheimer 31^st Annual Virtual Healthcare Conference: The company will present on Thursday, March 18, 2021, at 10:40 a.m. ET and will participate in one-on-one meetings during the conference.

About Fortress Biotech
Fortress Biotech, Inc. (“Fortress”) is an innovative biopharmaceutical company that was ranked in Deloitte’s 2019 and 2020 Technology Fast 500™, annual rankings of the fastest-growing North American companies in the technology, media, telecommunications, life sciences and energy tech sectors, based on percentages of fiscal year revenue growth over three-year periods. Fortress is focused on acquiring, developing and commercializing high-potential marketed and development-stage drugs and drug candidates. The company has five marketed prescription pharmaceutical products and over 25 programs in development at Fortress, at its majority-owned and majority-controlled partners and at partners it founded and in which it holds significant minority ownership positions. Such product candidates span six large-market areas, including oncology, rare diseases and gene therapy, which allow it to create value for shareholders. Fortress advances its diversified pipeline through a streamlined operating structure that fosters efficient drug development. The Fortress model is driven by a world-class business development team that is focused on leveraging its significant biopharmaceutical industry expertise to further expand the company’s portfolio of product opportunities. Fortress has established partnerships with some of the world’s leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including Alexion Pharmaceuticals, Inc., AstraZeneca, City of Hope, Fred Hutchinson Cancer Research Center, St. Jude Children’s Research Hospital and Nationwide Children’s Hospital. For more information, visit www.fortressbiotech.com.

Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. As used below and throughout this press release, the words “we”, “us” and “our” may refer to Fortress individually or together with one or more partner companies, as dictated by context. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; risks relating to the timing of starting and completing clinical trials; our dependence on third-party suppliers; risks relating to the COVID-19 outbreak and its potential impact on our employees’ and consultants’ ability to complete work in a timely manner and on our ability to obtain additional financing on favorable terms or at all; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The information contained herein is intended to be reviewed in its totality, and any stipulations, conditions or provisos that apply to a given piece of information in one part of this press release should be read as applying mutatis mutandis to every other instance of such information appearing herein.

Company Contacts:
Jaclyn Jaffe and William Begien
Fortress Biotech, Inc.
(781) 652-4500
ir@fortressbiotech.com

Investor Relations Contact:
Daniel Ferry
LifeSci Advisors, LLC
(617) 430-7576
daniel@lifesciadvisors.com

Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
tplohoros@6degreespr.com  

FAQ

What are the upcoming investor conferences for Fortress Biotech (FBIO) in March 2021?

Fortress Biotech (FBIO) will participate in four virtual investor conferences in March 2021, including H.C. Wainwright on March 9, Barclays on March 11, ROTH Conference on March 16, and Oppenheimer on March 18.

When will Fortress Biotech's presentation be available for the H.C. Wainwright Conference?

The presentation for the H.C. Wainwright Global Life Sciences Virtual Conference will be available on Fortress’ website starting March 9, 2021, at 7:00 AM ET.

What is Fortress Biotech's focus in biopharmaceutical products?

Fortress Biotech focuses on acquiring, developing, and commercializing promising biopharmaceutical products across multiple market areas, including oncology and rare diseases.

Who is the CEO of Fortress Biotech (FBIO) participating in the investor conferences?

Lindsay A. Rosenwald, M.D., is the Chairman, President, and Chief Executive Officer of Fortress Biotech (FBIO) participating in the investor conferences.

How can I access the webcast for the ROTH Conference involving Fortress Biotech (FBIO)?

The webcast for Fortress Biotech's fireside chat at the ROTH Conference on March 16, 2021, will be available on their website for approximately 30 days following the event.